Literature DB >> 14979736

A study of the response of elderly patients with end-stage renal disease to epoetin alfa or beta.

Johann C B Nicholas1.   

Abstract

BACKGROUND: Anaemia correction in patients with end-stage renal disease has been enhanced following the use of epoetin alfa or beta and there are a number of studies detailing its application. Dialysis centres are dealing with greater numbers of elderly patients and anaemia correction in these individuals may differ by virtue of co-existing comorbidity and their age.
OBJECTIVE: The aim of this study was to examine the response of the elderly patients to anaemia correction using a locally devised anaemia correction protocol while receiving dialysis.
METHODS: An incident, non-randomised, cohort observational study in a single centre was used to compare the correction of anaemia in a population of elderly (> or =65 years of age) and young dialysis patients. All incident patients starting peritoneal dialysis and haemodialysis (HD) between January 1998 and December 2000 were selected and treated using a locally devised anaemia correction protocol and observed for at least 1 year. Anaemia correction following adjustments for factors such as age, comorbidity, dialysis type, dialysis access type and predialysis nephrological care was assessed.
RESULTS: 198 patients commenced dialysis with 86 elderly patients (mean age +/- SD 73.7 +/- 4.9 years). The elderly patients had similar periods of predialysis nephrological care as the younger patients. Most patients received HD and required a tunnelled dialysis catheter (TC) as vascular access. Equivalent numbers of elderly patients received peritoneal dialysis. Comorbid scores were greater in the elderly and patient survival was dependent upon these comorbid factors. Following the strict use of TCs, patient survival was similar to those patients commencing HD with arterio-venous fistulae. Anaemia correction in the elderly was similar to the younger patients, with a median haemoglobin of 11.3 g/dL. By 6 months of dialysis, most patients achieved the UK Renal Association anaemia correction standard (haemoglobin above 10 g/dL). The elderly patients maintained significantly higher serum ferritin levels throughout (median 209 microg/L) and required less epoetin alfa or beta (median 91.6 units/kg/wk), indicating that functional iron deficiency in the elderly dialysis patients is less. Intravenous iron sucrose doses were similar in both age groups and iron overload (serum ferritin above 800 microg/L) had been avoided following the use of the intravenous iron protocol.
CONCLUSION: The study has noted that elderly patients responded to anaemia corrective therapies as well as the younger patients, despite greater levels of comorbidity while requiring less epoetin alfa or beta.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14979736     DOI: 10.2165/00002512-200421030-00004

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  42 in total

1.  Longer duration of predialysis nephrological care is associated with improved long-term survival of dialysis patients.

Authors:  P Jungers; Z A Massy; T Nguyen-Khoa; G Choukroun; C Robino; F Fakhouri; M Touam; A T Nguyen; J P Grünfeld
Journal:  Nephrol Dial Transplant       Date:  2001-12       Impact factor: 5.992

2.  What is the most appropriate strategy to monitor functional iron deficiency in the dialysed patient on rhEPO therapy? Merits of percentage hypochromic red cells as a marker of functional iron deficiency.

Authors:  I C Macdougall
Journal:  Nephrol Dial Transplant       Date:  1998-04       Impact factor: 5.992

Review 3.  Iron overload and cardiovascular complications in dialysis patients.

Authors:  Josef Kletzmayr; Walter H Hörl
Journal:  Nephrol Dial Transplant       Date:  2002       Impact factor: 5.992

4.  Serum ferritin is a marker of morbidity and mortality in hemodialysis patients.

Authors:  K Kalantar-Zadeh; B R Don; R A Rodriguez; M H Humphreys
Journal:  Am J Kidney Dis       Date:  2001-03       Impact factor: 8.860

5.  Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration.

Authors:  J Parkkinen; L von Bonsdorff; S Peltonen; C Grönhagen-Riska; K Rosenlöf
Journal:  Nephrol Dial Transplant       Date:  2000-11       Impact factor: 5.992

6.  A randomized controlled study of iron supplementation in patients treated with erythropoietin.

Authors:  I C Macdougall; B Tucker; J Thompson; C R Tomson; L R Baker; A E Raine
Journal:  Kidney Int       Date:  1996-11       Impact factor: 10.612

7.  Clinical utility of the reticulocyte hemoglobin content in the diagnosis of iron deficiency.

Authors:  Alan E Mast; Morey A Blinder; Qing Lu; Sherri Flax; Dennis J Dietzen
Journal:  Blood       Date:  2002-02-15       Impact factor: 22.113

8.  Percentage hypochromic red cells and the response to intravenous iron therapy in anaemic haemodialysis patients.

Authors:  C H Jones; D Richardson; S Ayers; C G Newstead; E J Will; A M Davison
Journal:  Nephrol Dial Transplant       Date:  1998-11       Impact factor: 5.992

9.  Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease.

Authors:  Tilman Drüeke; Véronique Witko-Sarsat; Ziad Massy; Béatrice Descamps-Latscha; Alain P Guerin; Sylvain J Marchais; Valérie Gausson; Gérard M London
Journal:  Circulation       Date:  2002-10-22       Impact factor: 29.690

10.  Incidence of anaemia, and use of epoetin therapy in pre-dialysis patients: a prospective study in 403 patients.

Authors:  Pierre-Yves Jungers; Christophe Robino; Gabriel Choukroun; Thao Nguyen-Khoa; Ziad A Massy; Paul Jungers
Journal:  Nephrol Dial Transplant       Date:  2002-09       Impact factor: 5.992

View more
  1 in total

1.  A randomised single-blind study to improve health-related quality of life by treating anaemia of chronic kidney disease with Aranesp® (darbepoetin alfa) in older people: STIMULATE.

Authors:  Simon D Roger; Sarbjit V Jassal; Michael C Woodward; Steven Soroka; Lawrence P McMahon
Journal:  Int Urol Nephrol       Date:  2013-08-28       Impact factor: 2.370

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.